Genomic Expression
Genomic Expression operates the OneRNA platform, a quantitative whole-transcriptome RNA sequencing system for cancer diagnostics that matches patients to approved drugs and clinical trials. It serves hospitals deploying the platform in-house, clinicians, and pharma companies developing companion diagnostics.
- Company typePrivate
- Founded2009
- HeadquartersBeverly, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Genomic Expression does
Genomic Expression operates the OneRNA® Platform, a quantitative CLIA-validated whole-transcriptome RNA sequencing system that analyzes approximately 20,000 mRNAs from real clinical samples including archival FFPE, CTCs, and liquid biopsies (blood, saliva, urine). The platform's proprietary sample preparation technology, invented by CSO and co-founder Morten Pedersen, enables RNA-seq in samples where RNA is typically destroyed. Patient RNA profiles are compared against a curated true-normal tissue database to statistically power diagnostic conclusions, and a curated drug-target-ligand database connects abnormally expressed genes to approved treatments and clinical trials. The company reports a diagnostic yield of close to 100% in matching patients to approved drugs, versus approximately 40% for DNA panels. The product surface has expanded with OneRNA® CDx AI, a companion diagnostics module that delivers an algorithm-based AI endpoint for pharma partners at a stated development cost of under $1M per program.
The company serves three customer segments: hospitals and healthcare systems (deploying OneRNA in their own CLIA labs with proprietary reagents, APIs, and HIPAA-compliant EMR integration under RNA-seq-specific payer codes); clinicians and oncologists (referring individual patient cases when standard treatment fails or cancer recurs); and pharmaceutical and biotech companies (target validation, companion diagnostics development, label expansion, and clinical study support, including rescue of failed drugs). Revenue mechanics span transaction-fee CLIA diagnostic testing, recurring hospital platform licensing, and professional services for pharma research and CDx development, with all pricing conducted on a quote-based, non-public basis. Distribution is direct and enterprise-led, with no channel or reseller model.
Genomic Expression is a privately held company headquartered in Beverly, Massachusetts, founded in 2009, with 1-10 employees. The company has raised approximately $6.5M cumulatively through grants from the Danish Innovation Fund, Horizon Europe, EuroStars, and the US National Cancer Institute, plus angel funding from Pipeline Angels and Harvard Business Angels, with additional disclosed rounds including a 2017 EISMEA grant and a 2018 financing. Management is led by CEO and co-founder Gitte Pedersen (former Novo Nordisk executive) alongside CSO Morten Pedersen and CMO Jesper Zeuthen (co-founder of GeneMap and Topotarget, both of which completed IPOs). The company is CLIA-validated, HIPAA-compliant, and has received recognition including Forbes feature, EIC Lifescience Award, MedTech Innovator Top 50, XTC Top 10, and XPRIZE Rapid Covid Testing semifinalist.
Genomic Expression firmographics
Firmographics- Name
- Genomic Expression
- Legal name
- Genomic Expression
- Website
- https://genomicexpression.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Genomic Expression operates the OneRNA platform, a quantitative whole-transcriptome RNA sequencing system for cancer diagnostics that matches patients to approved drugs and clinical trials. It serves hospitals deploying the platform in-house, clinicians, and pharma companies developing companion diagnostics.
- Ownership category
- akta.pro rank
Genomic Expression industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
- akta.pro secondary industries
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Genomic Expression is headquartered
LocationHeadquarters
- HQ city
- Beverly
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Genomic Expression business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- CLIA Diagnostic Testing Services: RNA-seq based cancer diagnostics performed in CLIA-certified lab, billed under RNA-seq-specific payer code. Revenue from diagnostic testing services matched to drugs and clinical trials.
- Hospital Platform Licensing: Hospitals implement OneRNA platform in their own CLIA labs using proprietary reagents and APIs, generating new revenue under RNA-seq payer codes.
- Pharma Research Services: Target validation, companion diagnostics development, and clinical study support services for biotech and pharma companies. CDx development under $1M with algorithm deliverables.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels3 records
Genomic Expression product offering
Product offeringCore offering
Genomic Expression provides the OneRNA® Platform, a CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from real clinical samples (archival FFPE, CTCs, liquid biopsy) to detect disease and match oncology patients to approved drugs and clinical trials. The company commercializes this technology through three models: CLIA-certified diagnostic testing services reimbursed under RNA-seq-specific payer codes, licensing of the platform into hospital CLIA labs with proprietary reagents and APIs, and pharma research services for target validation, companion diagnostics development, and clinical study support.
Product overview
Genomic Expression offers a single unified platform, the OneRNA® Platform, augmented by a companion diagnostics module called OneRNA® CDx AI. The core OneRNA® Platform is a quantitative, CLIA-validated whole-transcriptome RNA-seq system that analyzes approximately 20,000 mRNAs from archival FFPE, CTCs, and liquid biopsy samples to match nearly all patients to approved drugs or clinical trials. The OneRNA® CDx AI module extends the platform by enabling pharmaceutical companies to derive companion diagnostics directly from whole-transcriptome data on an AI endpoint. Both offerings share the same underlying RNA-seq technology, sample types, and clinical validation infrastructure, with the CDx module representing a specialized application for drug development and label expansion.
Differentiator
Problem solved
Functional benefit
Brands
- OneRNA®: A quantitative CLIA-validated whole-transcriptome RNA sequencing platform that analyzes all mRNAs to detect disease, match patients to drugs, and enable precision medicine in oncology.
Products and services
- OneRNA® Platform Quantitative, CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from patient samples including archival FFPE, circulating tumor cells, and liquid biopsies (blood, saliva, urine) to detect disease, monitor health, and match cancer patients to approved drugs and clinical trials with close to 100% diagnostic yield. Compares patient RNA against a database of true normal tissue and connects abnormal gene expression to a curated drug-target-ligand database of approved treatments and clinical trials.
- CLIA-Certified RNA Diagnostic Testing Services Diagnostic testing services performed in Genomic Expression's CLIA-certified laboratory using the OneRNA® Platform, billed under RNA-seq-specific payer codes and accepted by Medicare and select private payors. Delivers diagnostic reports matching patients to approved drugs and clinical trials.
- OneRNA Platform Deployment for Hospital CLIA Labs Enterprise platform implementation service that installs the OneRNA® Platform in a hospital's own CLIA-certified laboratory, including proprietary reagents, APIs, and HIPAA-compliant EMR integration, enabling the hospital to run quantitative whole-transcriptome RNA diagnostics in-house and capture reimbursement under RNA-seq-specific payer codes.
- Pharma RNA Research & Companion Diagnostics Services Research and development services for biotech and pharmaceutical partners, covering target validation using whole-transcriptome RNA, companion diagnostic (CDx) development with algorithm deliverables under $1M, clinical study design and support, label expansion, and rescue of failed drug programs using real patient RNA data.
Quantifiable outcome
- Close to 100% diagnostic yield matching patients to approved drugs (vs 40% for DNA panels, dropping to 26% in low mutation tumors)
- +3 more outcomes
Companies that use Genomic Expression
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Genomic Expression technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Genomic Expression partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Genomic Expression competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine (Roche): Foundation Medicine is the dominant DNA-based comprehensive genomic profiling provider for oncology, serving hospitals, oncologists, and pharma CDx partners. It is comparable because it sells tumor profiling into the same hospital and pharma channels, but it is anchored on DNA panel content where Genomic Expression's whole-transcriptome approach claims superior yield.
- Guardant Health: Guardant Health is a leading liquid-b biopsy and genomics company offering Guardant360 for tumor profiling and GuardantINFINITY for multi-omics including RNA. It is comparable because it serves oncology clinicians, hospitals, and pharma with tumor molecular profiling, with an increasing focus on RNA expression that overlaps with OneRNA's whole-transcriptome thesis.
- Natera: Natera is a molecular diagnostics company offering cell-free DNA and RNA-based tests across oncology (Signatera for MRD) and reproductive health. It is comparable as a CLIA-certified molecular diagnostics operator with hospital and pharma channels, though anchored in cell-free DNA MRD rather than whole-transcriptome tumor profiling.
- Tempus AI: Tempus is a large-scale AI-powered precision medicine company offering multi-modal sequencing (DNA and RNA), clinical data, and analytics for oncology. It is broadly comparable as an oncology sequencing and data platform targeting hospitals, clinicians, and pharma, but operates at far greater scale and with DNA-first workflows that Genomic Expression's RNA-first platform aims to differentiate against.
- NeoGenomics: NeoGenomics is a clinical oncology laboratory offering comprehensive genomic profiling, including RNA fusion and expression assays, to hospitals and oncologists. It competes in the same hospital and CLIA diagnostic channel but with a much broader menu and footprint; relevant as an incumbent reference lab that Genomic Expression must displace or partner with.
- Exact Sciences (Abbott): Exact Sciences, recently acquired by Abbott for ~$20B per company materials, is a major molecular diagnostics franchise with oncology screening and profiling products. It illustrates the size and M&A appetite for sequencing-based cancer diagnostics and is broadly comparable as a large-scale oncology molecular diagnostics operator.
- Veracyte: Veracyte is a genomic diagnostics company offering RNA-based and multi-omics tests in oncology (e.g., Afirma for thyroid, Decipher Prostate). It is comparable as an RNA-first diagnostics operator serving hospitals and clinicians, but focused on specific indications rather than whole-transcriptome pan-oncology profiling.
Direct peers
- Personalis: Personalis provides ImmunoID Next, a comprehensive tumor profiling platform combining whole-genome, exome, and RNA sequencing for oncology and immuno-oncology applications. Comparable as a direct competitor in whole-transcriptome tumor analysis serving pharma and clinical customers, with a similar emphasis on immune-therapy target and tumor microenvironment detection.
- Caris Life Sciences: Caris offers multi-omics tumor profiling including whole-transcriptome RNA sequencing (MI Profile) plus DNA and protein analysis for oncology. It is the closest direct peer because it provides RNA-based molecular profiling and companion diagnostics to clinicians, hospitals, and pharma on a CLIA-certified basis, directly competing for the same diagnostic yield narrative.
- Adaptive Biotechnologies: Adaptive Biotechnologies applies immune repertoire sequencing (T-cell and B-cell receptor sequencing via RNA) to oncology minimal residual disease and immune profiling. Comparable as an RNA-sequencing-driven diagnostics company serving pharma and clinicians, though focused on immune receptor rather than whole-transcriptome tumor profiling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Genomic Expression social profiles
Digital presenceGenomic Expression compliance and trust
Trust signalCompliance2 records
Genomic Expression financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genomic Expression leadership team
Management profileNumber of profiles
Profiles3 records
Genomic Expression funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genomic Expression M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genomic Expression
What does Genomic Expression do?
Genomic Expression provides the OneRNA® Platform, a CLIA-validated whole-transcriptome RNA sequencing platform that analyzes approximately 20,000 mRNAs from real clinical samples (archival FFPE, CTCs, liquid biopsy) to detect disease and match oncology patients to approved drugs and clinical trials. The company commercializes this technology through three models: CLIA-certified diagnostic testing services reimbursed under RNA-seq-specific payer codes, licensing of the platform into hospital CLIA labs with proprietary reagents and APIs, and pharma research services for target validation, companion diagnostics development, and clinical study support.
Is Genomic Expression a public or private company?
Genomic Expression is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Genomic Expression founded?
Genomic Expression was founded in 2009. It employs 1 to 10 people.
Where is Genomic Expression based?
Genomic Expression is headquartered in Beverly, United States, in the North America region.
How does Genomic Expression make money?
Three revenue lines are on record. CLIA Diagnostic Testing Services are the primary driver. The others are hospital Platform Licensing and pharma Research Services.
Who are Genomic Expression's main competitors?
Broad incumbents on record are Foundation Medicine (Roche), Guardant Health, Natera, Tempus AI, NeoGenomics, Exact Sciences (Abbott) and Veracyte. Direct peers are Personalis, Caris Life Sciences and Adaptive Biotechnologies.
Does Genomic Expression have an API?
No public API is recorded for Genomic Expression.
What industry is Genomic Expression in?
Genomic Expression's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGANAE, Transcriptomics & Gene Expression Profiling Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.